Disclosures: Cara Mack: Nothing to Disclose, Alexander Miethke: Mirum Pharmaceutical Inc: Grant/Research Support, Mirum Pharmaceutical Inc: Consultant, Ipsen: Speaking and Teaching, Kieran Hawthorne: Nothing to Disclose, Lisa Henn: Murata Vios: Consultant, Simon Horslen: Nothing to Disclose, Shika Sundaram: Nothing to Disclose, Estella Alonso: Nothing to Disclose, Nitika Gupta: Nothing to Disclose, Binita Kamath: Mirum: Consultant, Mirum: Grant/Research Support, Albireo/Ipsen: Consultant, Albireo/Ipsen: Grant/Research Support, Audentes: Consultant 2353 OBETICHOLIC ACID FOR PRIMARY BILIARY CHOLANGITIS IN THE PREVENTION OF CLINICAL EVENTS: A MODELING STUDY USING REAL-WORLD DATA Zobair Younossi 1 Alexandra Ellis 2 Jackie Lee 3 Leona Bessonova 4 Radhika Nair 4 Elizabeth Potente 4 Robert Gish 5 , 1 The Global Liver Council, Center for Outcomes Research in Liver Disease, Washington, DC, USA, 2 Stratevi, Boston, Massachusetts, USA, 3 Stratevi, Santa Monica, California, USA, 4 Intercept Pharmaceuticals, Morristown, New Jersey, USA, 5 Robert G
The method for producing highly stable reduced glutathione for injection according to claim 1, wherein: in step 5, the freeze-drying comprises the steps of, preparing liquid and filling at 20-30 , putting a sample into a freeze dryer, quickly reducing the temperature of a plate layer to-40 , preserving heat for 1h, when the temperature of a partition plate is-10 +/-2 , preserving heat for 1h, quickly reducing the temperature of the plate layer to-40 within 1h, preserving heat for 3h, transferring to a cold trap at-50 , vacuumizing to below 10Pa, firstly preserving the temperature of the plate layer at-5 for 3h, then heating the plate layer to 10 within 3h, when a product is at 0 , starting to increase the temperature of the plate layer to 40 , and when the product is increased to 30 , preserving heat for 5 h
HILFT DIE L-CARNITIN-WIRKUNG BEI DER FETTVERBRENNUNG
Who is GHK-CU Peptide Serum suitable for
Sreekumar, P
